iBio begins phase 1 trial of obesity drug IBIO-600

June 2, 2026 7:00 AM

iBio Inc. (NASDAQ: IBIO) announced it has dosed the first participant in a Phase 1 clinical trial of IBIO-600, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found